HAVCR2 and metabolic dysfunction-associated steatotic liver disease: This study aims to explore how macrophage TIM3 drivers NAFLD-associated chronic liver injury as well as identify a subtype of fibrotic patients suitable for anti-TIM3 immunotherapy.